Artes has announced that a new EU based grant of patent for their well-proven virus-like-particle (VLP) technology platform Metavax.
“The new patent integrates exactly in our existing patent portfolio and will further strengthen our technology offer”, said Dr. Melanie Piontek, business development director of Artes. “In combination with our proprietary yeast expression technology our antigen presentation platform Metavax is an excellent and unique tool for the development of effective, safe and affordable vaccines.”
Currently, the platform Metavax is used in several clients’ projects as well as in several in-house research projects. Within the “Plurivax” project, funded by the German Federal Ministry of Education and Research (BMBF) as part of the 8th EuroTransBio call, Artes enhances its VLP based vaccine platform Metavax and develops processes especially suited for the veterinary applications.
“Our intellectual property strategy is to provide multiple layers of protection for our technology platform portfolio. With this new patent, we have additional reinforcement to our existing patent estate,” said Dr. Melanie Piontek.
Artes is a globally working, well established and reliable technology provider for recombinant protein production. The company develop microbial cell lines and processes for vaccines, biopharmaceuticals, biosimilars and enzymes and offer ready-to-transfer processes for a wide range of products.
Artes' vlp technology, metavax receives, european patent
4.jpg)